IBCN 2018: Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence.
In summary, they showed a strong prognostic potential of ctDNA in bladder cancer at the time of diagnosis, suggesting a potential role for ctDNA in the staging of bladder cancer. Incorporation of ctDNA analysis into routine follow-up may allow earlier initiation of alternative treatment modalities. Further external validation and cost comparison of ctDNA versus other biomarkers are needed.
Presented by: Karin Birkenkamp-Demtröder, MSci, Ph.D., Clinical Research Unit, Aarhus University Hospital, Aarhus, Denmark
Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 16th Annual Meeting of the International Bladder Cancer Network (IBCN) October 11-13, 2018 - the Inntel Hotels Rotterdam Centre, Rotterdam, The Netherlands